ZYUS Strengthens Leadership Team with Appointment of Vice President of Clinical Research
09 Enero 2024 - 6:00AM
Business Wire
Scott Livingstone brings extensive healthcare
expertise and strategic leadership to ZYUS’ experienced team
ZYUS Life Sciences Corporation (the “Company”) (TSX-V: ZYUS), a
Canadian-based life sciences company leading scientific research
and global development of innovative cannabinoid-based
pharmaceutical drug products, today announced that it has
strengthened its leadership team with the appointment of Scott
Livingstone to the role of Vice President of Clinical Research with
its wholly owned subsidiary, ZYUS Life Sciences Inc. In this
instrumental role, Mr. Livingstone will lead the Company’s clinical
research initiatives and oversee ZYUS’ Phase 2 Clinical Trial aimed
at evaluating the efficacy, safety, and tolerability of
Trichomylin® softgel capsules in patients with advanced cancer and
moderate to severe cancer-related pain.
In addition to a wealth of experience in healthcare, Mr.
Livingstone holds a Bachelor of Science in Pharmacy and a Master of
Science in Clinical Pharmacy, both from the University of
Saskatchewan. Scott has a proven track record of operational
success in both public and private healthcare sectors, including
hospital and community pharmacy practice, social sector policy and
health care informatics. Prior to joining ZYUS, Mr. Livingstone
served as the CEO of the Saskatchewan Health Information Network
(now eHealth Saskatchewan), President and CEO of the Saskatchewan
Cancer Agency, chair of both the National Steering Committee and
the Saskatchewan Provincial Advisory Committee for the Pan Canadian
Oncology Drug Review, and the inaugural President and CEO of the
Saskatchewan Health Authority. These leadership positions have
enabled Mr. Livingstone to play an active role in evidence-based
assessment of oncology drugs, oncology drug safety and the
sustainability of cancer control which, together with his passion
for patient safety and patient-centered approach to care, makes Mr.
Livingstone an ideal fit for ZYUS and its clinical research
initiatives.
"We are pleased to announce Scott Livingstone's appointment to
VP of Clinical Research with ZYUS Life Sciences Inc.," said Brent
Zettl, President and CEO of the Company. "His leadership and
experience will be instrumental in guiding our clinical research
initiatives, particularly in overseeing the Phase 2 Clinical Trial
for Trichomylin softgel capsules. This strategic addition to our
team reaffirms ZYUS’ commitment to the development of
evidence-based solutions to address unmet patient needs.”
“I'm honored to lead ZYUS’ clinical research initiatives, driven
by a profound dedication to improving lives through innovative
discoveries,” said Mr. Livingstone. “With a dedicated team and a
relentless pursuit of scientific innovation, we aim to uncover
transformative cannabinoid-based therapies that benefit patients
globally.”
About the Phase 2 Clinical Trial
Following the Company’s announcement on December 5, 2023, ZYUS
is moving forward with the decision to fast-track and progress
directly to a full Phase 2 Clinical Trial in Canada. This trial
aims to evaluate the preliminary efficacy, safety, and tolerability
of Trichomylin softgel capsules in patients with advanced cancer
and moderate to severe cancer-related pain.
About ZYUS Life Sciences Corporation
ZYUS is a publicly traded Canadian-based life sciences company
focused on the global development and commercialization of
regulated cannabinoid-based pharmaceutical drug product candidates.
Through clinical research, ZYUS is committed to furthering the
understanding of cannabinoids with the clinical development of its
pharmaceutical drug product candidates and intellectual property
activities to protect its novel formulations. Additionally, ZYUS is
dedicated to delivering high quality, cGMP/EU GMP-compliant
cannabinoid products to patients through the exempt global medical
market. The ZYUS vision is to reimagine the potential of pain
therapeutics by pursuing regulatory approval of cannabinoid
formulations and elevating cannabinoids as a standard of care in
pursuit of transformational impact on patients’ lives. ZYUS:
Advancing the Science of Well-Being. For additional information,
visit www.zyus.com or follow us on X (formerly known as Twitter)
@ZYUSCorp.
Cautionary Note Regarding Forward-Looking Statements
This news release contains “forward-looking information” within
the meaning of applicable securities laws relating to the Company’s
business, the Company’s ability to advance clinical research
activities, realize on its objectives and obtain regulatory
approval of cannabinoid-based pharmaceutical drug product
candidates such as Trichomylin softgel capsules, introduce products
that act as alternatives to current pain management therapies,
advance Phase 2 clinical development of Trichomylin softgel
capsules and build shareholder value. Any such forward-looking
statements may be identified by words such as “expects”,
“anticipates”, “intends”, “contemplates”, “believes”, “projects”,
“plans” and similar expressions. Readers are cautioned not to place
undue reliance on forward-looking statements. Statements about,
among other things, the Company’s business, the Company’s ability
to advance clinical research activities, realize on its objectives
and obtain regulatory approval of cannabinoid-based pharmaceutical
drug product candidates such as Trichomylin softgel capsules,
introduce products that act as alternatives to current pain
management therapies, advance Phase 2 clinical development of
Trichomylin softgels, and build shareholder value are all
forward-looking information. These statements should not be read as
guarantees of future performance or results. Such statements
involve known and unknown risks, uncertainties and other factors
that may cause actual results, performance or achievements to be
materially different from those implied by such statements.
Although such statements are based on management’s reasonable
assumptions, there can be no assurance that the Company will be
able to advance its clinical research activities and further
operations, realize its objectives and obtain regulatory approval
of cannabinoid-based pharmaceutical drug product candidates,
introduce products that act as alternatives to current pain
management therapies or advance Phase 2 clinical development of
Trichomylin softgels. The Company assumes no responsibility to
update or revise forward-looking information to reflect new events
or circumstances or actual results unless required by applicable
law. Neither the TSXV nor its Regulation Services Provider (as that
term is defined in the policies of the TSXV) accepts responsibility
for the adequacy or accuracy of this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240109588167/en/
For more information, please contact:
ZYUS Media Inquiries media@zyus.com 1-833-651-7723
ZYUS Investor Relations investors@zyus.com
Zyus Life Sciences (TSXV:ZYUS)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
Zyus Life Sciences (TSXV:ZYUS)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
